Drug Trial Radar · NCT04221919
Different β -Blockers in STEMI and Primary PCI
Last checked: Nov 19, 2026Latest source record: Jan 9, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,200
Planned (sponsor's estimate)
Start
Jan 2020
Primary completion
Jan 2021
Study completion Jan 2025
Sponsor
- Lead sponsor
- Qilu Hospital of Shandong UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 9, 2020
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Carvedilol, target dose: 50 mg daily; Bisoprolol, target dose: 10 mg daily; Metoprolol tartrate, target dose: 150 mg daily; Metroprolol succinate, target dose: 200 mg daily
Conditions
- Primary PCI
Interventions
β -BlockersDrug
Target doses of carvedilol, bisoprolol, metoprolol tartrate, or metroprolol succinate
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in LVEDV from baselineTime frame: 1 to 5 years
- Major adverse cardiovascular events (MACE)Time frame: 1 to 5 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.